Exhibit 99.1 Immutep Limited Preliminary final report 2. Results for announcement to the market Explanation of the above information: | --- | --- | |------------------------------------|---------------------------------| | | | | | | | Name of entity: | Immutep Limited | | ABN: | 90 009 237 889 | | Reporting period: | Year ended 30 June 2024 | | Previous corresponding period: | Year ended 30 June 2023 | | --- | --- | --- | --- | --- | |------------------------------------------------------------------------- ...

SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present at the following investor conferences: Canaccord Genuity 44th Annual Growth Conference Location: InterContinental Boston Hotel, Boston, MA Date: Wednesday, 14 August 2024 Time: 08:30am – 8:55am ET Baird 2024 Global Healthcare Confe ...

Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line non-small cell lung cancer in a pivotal Phase III trial Continuing positive clinical data reported from efti: Positive results from TACTI-003 Phase IIb trial in first-line head and neck squamous cell carcinoma with efti in combination with KEYTRUDA® Encouraging efficacy and safety data from A ...

Media Release Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD's antiPD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer TACTI-004 registrational trial will enrol ~750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy SYDNEY, AUSTRALIA, July 22, 2024 (GLOBE NEWSWIRE) -- I ...

Core Insights - Immutep's proprietary soluble LAG-3 protein, efti, is being developed as a cancer treatment in combination with Merck's Keytruda, showing promising results in clinical trials for head and neck squamous cell carcinoma (HNSCC) [1][10]. Efficacy and Safety - The combination therapy of efti and Keytruda achieved an objective response rate (ORR) of 35.5% and a disease control rate (DCR) of 58.1% in patients with negative PD-L1 expression, significantly higher than historical controls [2][11]. - The treatment demonstrated a complete response rate of 9.7%, compared to 0% in historical controls for anti-PD-1 monotherapy [2]. - More than 50% of patients treated with the combination therapy have maintained their response for at least six months, with no new safety concerns reported [3]. Regulatory and Development Plans - Based on the positive efficacy and safety data, the company plans to engage with regulatory agencies regarding the next steps for efti [4]. - In addition to HNSCC, Immutep is exploring efti in combination with other agents for various solid tumors, including non-small cell lung cancer and metastatic breast cancer [5]. Market Position and Competitors - Merck's Keytruda continues to expand into new indications and markets, reinforcing its position in the oncology market, accounting for 47% of Merck's pharmaceutical sales in 2023 [6][14]. - Immutep currently holds a Zacks Rank 3 (Hold), while other companies in the biotech sector, such as Arcutis Biotherapeutics and Annovis Bio, have better rankings [7][15]. Stock Performance - Year to date, shares of Immutep have decreased by 3.7%, contrasting with a 2.5% decline in the industry [18].

Results Durability of Responses and Favourable Safety regulatory agencies. Efti has received FDA Fast Track designation in 1L HNSCC regardless of PD-L1 expression. The prevalence for CPS <1, CPS 1-19, and CPS >20 PD-L1 expression levels are approximately 20%, 30%, and 50% of the HNSCC patient population, respectively.3 KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. About Eftilagimod Alfa (Efti) Immutep is a clinical-stage biotechnology com ...

Guide to Identifying Oversold Stocks This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering IMMP in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 6.7% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term. Moreover, IMMP currently has a ...

SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules. Professor Andrew Godkin of Cardiff University said: "Our collaboration with Immutep has been exciting and fruitful, res ...

Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules. A number of promising compounds that block LAG-3, an immune checkpoint known to reduce the immune system' ...

The Institutional Offer raised gross proceeds of approximately A$89.6 million at an offer price of A$0.38 per New Share, consisting of approximately A$72.0 million under the Placement and approximately A$17.6 million under the Institutional Entitlement Offer. Dr Russell Howard, Chairman of Immutep, said: "Immutep has gone from strength to strength with the team working tirelessly to deliver our late-stage clinical program in three cancer areas: lung, breast, and head and neck cancer. As we traverse our path ...